Journal of pain & palliative care pharmacotherapy
-
J Pain Palliat Care Pharmacother · Mar 2015
Case ReportsDiscontinuance of life sustaining treatment utilizing ketamine for symptom management.
We present the case of an otherwise healthy 21-year-old female who developed severe respiratory failure following a minor procedure requiring ECMO and bi-level ventilation. During her protracted ICU course, she had significant difficulties with agitation and was titrated to the following regimen: hydromorphone 30 mg/hour, fentanyl 200 mcg/hour, dexmedetomidine 1.5 mcg/kg/hour, propofol at 70 mcg/kg/min, and midazolam at 20 mg/hour. We were consulted to assist in withdrawal of life prolonging measures at the family's request and given high doses of commonly used opioid and sedative medications successfully utilized methadone and ketamine for symptom control. This case study would indicate that in selected patients on high dose opioid and sedative medications prior to withdrawal of life prolonging measures ketamine may be considered for symptom management.
-
Questions from patients about pain conditions, analgesic pharmacotherapy, and responses from authors are presented to help educate patients and make them more effective self-advocates. In reply to a question about benign fasciculation syndrome, the presentation, causes, treatment, and chances of developing amyotrophic lateral sclerosis will be discussed.
-
J Pain Palliat Care Pharmacother · Mar 2015
The attractiveness of opposites: agonists and antagonists.
Opioid-induced bowel dysfunction, of which constipation is the most common aspect, is a major limiting factor in the use of opioids for pain management. The availability of an oral, long-acting formulation of oxycodone and naloxone represents a highly significant development in pain management. The combination of an opioid analgesic with an opioid antagonist offers reliable pain control with a significant reduction in the burden of opioid-induced constipation.
-
J Pain Palliat Care Pharmacother · Mar 2015
Chronic opioid pain management for chronic kidney disease.
Questions from patients about pain conditions, pain treatment, and responses from authors are presented to help educate patients and make them effective self-advocates. The topics addressed in this issue are renal or kidney failure and chronic pain management with opioids, morphine, and oxycodone effect in the body over a period of time. This includes process of absorption, distribution, localization in tissues, biotransformation and excretion in chronic kidney disease, expected side effects and recommendations.
-
The neurobiology of pain and analgesia exhibits plasticity in different pain states. Animal models allow the study of the pathways, neuronal plasticity, and pharmacology that reflect the pains many patients have. Inherited pain disorders may also indicate the pain-related roles of gene products. ⋯ Pain remains a subjective experience, and the search for objective measures or biomarkers of pain has so far not yielded definitive results. However, rational, mechanistic explanations for pain states are emerging, and a number of potential treatment targets that have recently been revealed by animal models of clinical pain conditions are beginning to be translated to the patient. This article outlines some of the major recent developments in preclinical and clinical pain science that have the potential to shape the development of new treatments for pain.